The company has been selected by the Cell Therapy Catapult (CTC) to develop its BioScience Catalyst Campus in Stevenage.
The CTC is part of a group of government funded independent centres called 'Catapults' designed to directly connect next generation technology businesses with the UK's research and academic communities.
The new facility will be able to manufacture late phase clinical trials and early supplies of advanced therapeutic medicinal products (ATMP's) including cell and gene therapies.
-- Advertisement --
The centre is to be complete in 2017.
Spencer Baber, MD at M+W Group UK said: "M+W Group is a specialist contractor for the construction of state-of-the-art facilities within the Life Sciences sector. We are proud to be associated with a government funded project of this specific nature which will see the UK established as the leading centre for the development of new and innovative medicinal products for the treatment of debilitating diseases such as blindness, diabetes and cancer."
Keith Thompson, CEO of the Cell Therapy Catapult, added: "I am delighted that we will be working with M+W Group, to create a centre that will advance industry in the UK to become a world leader in cell and gene therapy development and commercialisation."
(LM/CD)
